HPS Pharmacies wish to give notice that Sanofi-Aventis Australia, in consultation with the Therapeutic Goods Administration (TGA), has issued a product recall for diltiazem 60mg tablets as follows:
| Product | ARTG | Affected batches |
|---|---|---|
| Cardizem® 60mg | 73179 | 8149600 (Exp 04/2027)
8150154 (Exp 04/2027) |
| Vasocardol® 60mg | 73180 | 8151378 (Exp 10/2027) |
This product recall was initiated as a precautionary measure following detection of an impurity that is non-compliant with product registration.
Please inspect your stock and quarantine all products from the affected batches. If HPS Pharmacies provide imprest management services to your facility, an HPS representative will inspect all stock stored in the designated imprest areas at the earliest opportunity. All affected products will be quarantined for return to the supplier, and HPS Pharmacies will arrange for replacement stock as soon as possible. An HPS Pharmacies staff member will contact senior medical and nursing staff if there is an immediate impact to your facility.
Retain this notice in a prominent position, including in other related business units for one month. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Sanofi-Aventis Australia 1800 640 791, or your pharmacist at HPS Pharmacies.
Subscribe Knowledge Centre Updates
Enter your details to receive Knowledge Centre updates